Understand real-time human biology

Olink enables scientists to make research decisions more quickly and confidently through robust, multiplex protein biomarker analysis.

Learn more   ➔

Olink Explore 1536/384

Measure 1,536 proteins with unparalleled throughput, specificity & sensitivity with PEA technology and readout on NGS.

  • 1.3 million protein measurements/week/system
  • 384-plex analysis with exceptional data quality
  • Less than 3µL sample to screen the entire library
View Olink Explore 1536   ➔

Olink Target 96/48

Targeted protein biomarker discovery with disease or biology-focused 96- or 48-plex panels with qPCR readout.

  • Exceptional data quality - established and robust technology
  • Thorough, transparent validation - data you can trust
  • Flexibility to meet all needs - 16 carefully designed panels available
View Olink Target 96 / Target 48   ➔

Insights Stat Analysis app

Olink® Insights Stat Analysis simplifies data analysis by providing our customers with online tools for data visualization and statistical analyses.

Why Olink?

Olink offers high-quality protein biomarker discovery based on a flexible and scalable technology platform. Together with our customers we are accelerating proteomics to better understand human biology and develop future healthcare. Olink Target offers disease- or biology-focused 96- or 48-plex panels with qPCR readout for targeted discovery with exceptional quality. Olink Explore is a game-changing, high throughput proteomics solution with NGS readout, enabling almost 1500 proteins to be rapidly measured in a 384-plex format that maintains exceptional specificity, sensitivity and dynamic range. Why choose between throughput and quality when you can have the best of both worlds? Whatever your needs for protein biomarker discovery, Olink has the solution, with our unique, high quality and thoroughly validated Proximity Extension Assay (PEA) technology.

PEA technology - exceptional specificity

Olink’s unique Proximity Extension Assay (PEA) technology overcomes the significant specificity issues that were previously associated with high-multiplex immunoassays.

Dual recognition by pairs of oligonucleotide-linked antibodies creates a unique template for each protein and ensures a highly specific qPCR or NGS readout.

Read more about our PEA technology

View PEA technology video

Fastest growing, extensive protein library ~1500 proteins

Olink currently offers thoroughly validated, high-quality assays for over 1500 different human proteins. These are available via a range of disease- or biology-focused 92/48-plex panels with qPCR readout, or as our Olink Explore 1536 platform with NGS readout, available as the full library or as four 384-plex disease focused panels. This unique degree of flexibility enables researchers to select the scale of their studies according to their individual needs, from full discovery using our entire library, down to hypothesis-driven approaches using a single panel.

Olink Target 96 /48 human proteins

Olink Explore 1536/384 proteins

Truly scalable data you can trust

You can be confident that your Olink study will deliver reliable, reproducible results whether you are running a relatively small number of samples on a single panel, or a large cohort against our complete library. Olink delivers data you can really trust, as shown by our open access policy towards assay validation data, and the large number of peer-reviewed publications using Olink panels.

Data you can trust


Any questions? Visit our FAQ

Visit our FAQ section to find answers to our most frequently asked questions.

What our customers say

    • In profiling the immune systems of newborn children, the Olink panels allow us to maximize the amount of information extracted from a few microliters of plasma.

    • Assistant Professor Petter Brodin

    • Department of Medicine, Karolinska Institute, Stockholm
    • We have employed Olink panels in longitudinal deep phenotyping studies of over 5,000 individuals. We have found the data quality and reproducibility to be among the best of the high dimensional data strategies we have used.

    • Professor Leroy Hood

    • Institute for Systems Biology, Seattle
    • The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkers

    • Tom Lanz

    • Principal Scientist, Pfizer Neuroscience
    • My interest in biomarkers grew in parallel to the growth of Olink. Back in 2014, when I first selected the Olink technology for an important  EU-funded program that I was coordinating, the company had only a handful of employees. Since then, Olink’s growth was amazing. Yet, they still  behave like partners, not simple providers. I have since recommended Olink to many international colleagues.

    • Faiez Zannad

    • Professeur de Thérapeutique-Cardiologie Coordinateur, Centre d’Investigation Clinique Inserm, CHU, Université de Lorraine
    • Our work with Olink on plasma-based immuno-oncology (IO) applications has allowed the identification of tumor and immune changes associated with immune checkpoint inhibitor response/non-response.This is particularly exciting as we combine this technology with deep tumor-based analysis to understand tumor-immune interactions and establish predictive and/or monitoring tools for IO. The small volume required for Olink analysis is a game-changer as it allows multi-analyte assessment of samples and validation of findings by multiple orthogonal platforms.

    • Genevieve M. Boland

    • Director Melanoma Surgery Program, Massachusetts General Hospital, Boston
    • I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chains

    • Professor Tomas Olsson

    • Center for Molecular Medicine, Karolinska Hospital, Stockholm
    • Olink’s immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP)

    • Professor Mike Snyder

    • Department of Genetics, Stanford University
    • Olink has developed a very innovative technology that has a simplicity approach to be able to measure large numbers of proteins. That’s a significant breakthrough for investigators to break into a field of diseases that you could not explore without this technology.

    • Professor C.Thomas Caskey

    • Baylor College of Medicine, Houston TX
    • We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.

    • Professor Mathias Uhlen

    • Science for Life Laboratory & Royal Institute of Technology (KTH), Stockholm

Contact us

If you have any further questions about Olink Proteomics’ products or services, or would like to discuss your human protein biomarker discovery needs, please contact us:

Phone: +46 (0)18 – 444 39 70
Fax: +46 (0)18 – 50 93 00



Let us provide you with future updates about our products and services, as well as other professionally relevant information such as scientific meetings or publications connected to Olink Proteomics.

Sign up to our newsletter

Resources & support

In this section of our website, you will find a range of resources that provide product and application-related information that we hope will be useful for both the first time visitor who wishes to learn more about our solutions for protein biomarker discovery, development and implementation, as well as a source of reference for existing customers.

Go to Resources & support